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ABSTRACT 
Parallel groups of depressed (DSM III-R) outpatients received moclobemide (n = 22) and 
fluoxetine (n = 19), double blind, for 6 weeks. Respective starting doses were 150 mg twice a 
day and 20 mg q.a.m. These could be doubled after 3 weeks for greater efficacy. Chronic users of 
benzodiazepine anxiolytics continued taking them as comedication. Therapeutic and side effects 
were assessed using conventional rating scales. Actual driving performance was assessed during 
the week before therapy and at 1, 3 and 6 weeks thereafter using a standardized test that 
measures standard deviation of lateral position (SDLP). Similar remissions in depressive 
symptoms and side effects occurred in both groups. Patients drove with normal and reliable (r = 
0.87) SDLPs before treatments. Most continued to do so but a few drove with progressively 
rising SDLPs and the overall trends were significant in both groups (p < 0.03). A post-hoc 
multiple regression analysis was applied for identifying factors that correlated with SDLP in 
separate tests after the beginning of therapy. At 3 and 6 weeks there were significant (p < 0.03) 
relationships involving the same factor; patients who drove with progressively higher SDLPs 
appeared to be those using benzodiazepines that are metabolized by a P450 isozyme subject to 
inhibition by their particular antidepressant. 
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Information pertaining to driving performance of depressed outpatients before or during 
antidepressant drug therapy is relatively sparse. Pharmacoepidemiological survey indicate that 
unmedicated depressed patients drive with a higher than normal risk of becoming involved in 
injurious traffic accidents (Nelson, 1986), and that elderly patients treated with higher doses of 
sedative tricyclic antidepressants become involved in accidents more frequently than do age- 
and sex-matched normal control individuals (Ray et al., 1992; Leveille et al., 1994). However, 
there are as yet no epidemiological data concerning the effects on accident risk of modern 
antidepressants, such as the selective serotonin reuptake inhibitors or selective and reversible 
inhibitors of monoamine oxidase-A. 
The present attempt to measure the effects of moclobemide and fluoxetine on actual driving 
performance proceeded from similar research in healthy volunteers (Ramaekers et al., 1992, 
1995). In separate studies, individuals were treated with either moclobemide 200mg twice a day 
or fluoxetine 20 mg h.s. and with another antidepressant and placebo, for periods of 8 and 21 
days, respectively. Driving performance was assessed on treatment day 21 in the longer series. 
Neither moclobemide nor fluoxetine significantly affected the respective groups’ driving 
performance. From these results one would not expect either drug to impair the present 
patients’ driving performance, at least not over comparable treatment periods. However the 
patients’ treatments were scheduled to last longer than the volunteers’, so the possibility of 
belated driving impairment could not be excluded. The contrary could also be expected if the 
therapeutic effect of antidepressant treatment were to determine the patient’s driving 
performance. The remission of the patient’s symptoms during moclobemide or fluoxetine 
therapy might lead to driving improvement if their driving performance were generally deficient 
to begin with. There were still other reasons to suppose that the results of the previous studies 
might differ from those of the present study. It is far more difficult to control the influence of 
factors that can interact with antidepressants to affect performance in trials involving patients. 
One factor, prominent in the area where this study was conducted (Liège, Belgium), is the high 
prevalence of benzodiazepine (BZD) use (Ansseau, 1988; Petit et al., 1994). In Belgium, most 
patients suffering from depression are treated with an antidepressant and a BZD concurrently, 
particularly when the former has insomnia, anxiety or agitation as possible side effects. The 
protocol of the present study allowed patients entering the study to continue their longstanding 
use of BZD as comedication. 
This offered the opportunity of applying a post-hoc analysis to determine whether certain 
pharmacokinetic antidepressant-BZD interactions affect patients’ driving performance. 
Moclobemide and fluoxetine are known primarily to inhibit different cytochrome P450 isozymes 
that are responsible for the oxidative metabolism of many BZDs. The greatest inhibitory activity 
of moclobemide is at CYP2C19 and to a lesser extent also at CYP1A2 and CYP2D6 (Gram et al., 
1995). Inhibition of the latter produces no meaningful change in the pharmacokinetics of 
moclobemide (Guentert et al., 1995). Fluoxetine is a potent inhibitor of CYP2D6 as well as 
CYP3A3/4 (Lane et al., 1995). Some BZDs are substrates of CYP2C19, some are substrates of 
3A3/4, and others are substrates of none of the isozymes inhibited by the antidepressants. The 
BZD comedication used by patients in the present study could be either metabolically 
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competitive or noncompetitive with their particular antidepressant. The former might 
accumulate over time and cause the patient to drive progressively worse. That certain 
combinations of antidepressants and BZDs result in the latter’s accumulation in plasma 
accompanied by progressive performance impairment has already been demonstrated in 
healthy volunteers treated with either fluoxetine or nefazodone together with alprazolam 
(Lasher et al., 1991; Kroboth et al., 1995). 
Methods 
SUBJECTS 
Intake interviews were conducted by five psychiatrists under the supervision of the Professor of 
Psychiatry, University of Liège. Outpatients were included if they satisfied the following criteria: 
age 18-65 years, diagnosis of major depression according to DSM IIIR criteria, symptom severity 
associated with a score ≥ 17 on the 17-item Hamilton Depression Rating Scale (HDRS), 
possession of a valid driver’s license, and written informed consent after reading ‘Information 
for Volunteers’. Patients were excluded on the basis of the following: alcohol or drug abuse, or 
both; acute confusional state, delusions or hallucinations; hypersensitivity to the investigational 
drugs; serious concomitant illness or intercurrent disease; presumption of a need for 
hospitalization because of suicide or other factors; engagement in structured analytical or 
behavioural psychotherapy that might influence the course of the depressive illness during the 
trial, excluding psychotherapeutic support; renal or liver failure or previous viral or drug 
hepatitis; treatment with cimetidine; personality disorders presenting an important risk of 
noncompliance; occurrence of cerebrovascular accidents in the year before study entrance; 
duration of the present depressive episode of less than 2 weeks; use of fluoxetine within 5 weeks 
before study entrance; use of other marketed antidepressants or investigational drugs within 7 
days or electroconvulsive therapy within 4 weeks before study entrance; and, for women, 
pregnancy, lactation or the failure to use reliable contraceptives for less than 3 months. 
A total of 41 patients (25 men and 16 women) were included. Their demographics and 
diagnostic categorization are summarized in Table I. The study was carried out in accordance 
with the Declaration of Helsinki (Hong Kong Modification, 1989). The study protocol and 
information for volunteers were reviewed and approved by the standing Medical Ethics 
Committees of the Universities of Liège and Maastricht. 
DESIGN 
The study was conducted according to a two-leg, double-blind, parallel-group design. A period of 
3-7 days elapsed between patient enrollment and the beginning of trial medication. Then 
patients were randomly assigned to receive moclobemide 150mg twice a day or fluoxetine 20mg 
q.a.m. for 6 weeks (43 days). At the discretion of the attending psychiatrist this dosage could be 
doubled from day 22 on in case of insufficient efficacy. Moclobemide and fluoxetine were 
administered in identical appearing capsules containing 150mg and 20mg, respectively. One or 
two moclobemide capsules were taken in the morning and evening of every treatment day. One 
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or two fluoxetine capsules were taken in the morning, and matching placebo capsules were 
taken in the evening. Patients were instructed to take their medication after a meal. In order to 
ensure patient compliance with the medication regime, the returned medication was checked 
and counted at each visit. 
Concomitant BZD medication was allowed for patients who had already been prescribed a single 
drug for more than 3 months before study entrance. In these cases, prescription of the same BZD 
continued throughout the study. If needed, patients who had not used a BZD before study 
entrance were allowed to receive one or two doses of oxazepam, 10mg over the day or 30mg h.s. 
Type and dose of BZD comedication were filed in prescription records. Compliance with BZD 
prescription was not checked. Other psychoactive drug or electroconvulsive therapy were 
prohibited during trial. 
CLINICAL ASSESSMENTS 
Clinical assessments were conducted by the attending psychiatrists at day 1, 8, 15, 22 and 43. 
Beside the HDRS, the Montgomery-Asberg Depression Rating Scale (MADRS), Beck’s Depression 
Inventory (BDI), and a Clinical Global Impression (CGI) scale were used. In addition, the 
occurrence of side effects was checked using a standardized adverse events questionnaire. 
DRIVING ASSESSMENTS 
Patient undertook a driving test on six occasions. A training session and two baseline tests 
occurred during the week preceding the onset of treatment. Thereafter, driving performance 
was tested in the morning of day 8, 22 and 43 of treatment. Patients were met at home by an 
investigator and transported to the driving site. He/she then entered a primary highway (four 
lane, divided) at the beginning of a 100 km circuit between the Belgian cities Tongeren and 
Haelen. He/She proceeded to drive while attempting to maintain the vehicle at a constant speed 
(95 km/h) and steady lateral position between the delineated boundaries of the slower traffic 
lane. The patient was allowed to deviate from this procedure in order to pass slower vehicles 
travelling in the same lane. At an intersection halfway through the circuit, the patient drove off 
the highway and then reentered, travelling in the opposite direction. At the end of the driving 
test, the patient was driven home by the investigator. 
The patient was accompanied by a technician, whose task was to operate the equipment, and a 
licensed driving instructor seated in the front passenger’s seat with access to dual controls. His 
sole function was to ensure test safety. Patients were instructed to drive safely at all times and 
that the treatments might affect their ability to do so. They were informed of their legal 
responsibility to stop a test in progress if they felt for any reason that to continue would be 
unsafe. They were further informed that they would asked to stop by the instructor if, in his 
opinion, their physical appearance or driving performance indicated the possibility of a control 
loss. An electro-optical device mounted at the rear of the instrumented vehicle continuously 
measured the lateral distance separating the vehicle and the left lane-line. This signal was 
digitized at a rate of 4 Hz and stored on an onboard computer disk file for later editing and 
analysis. The off-line editing routine involved removal of all data segments that revealed signal 
loss, disturbance or occurrence of passing manoeuvres. The remaining clean data were then 
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used to calculate means and variance for lateral position. The square root of the variance or 
standard deviation of lateral position (SDLP) was then taken as the primary measure of driving 
performance. 
 
Table I. Patient demographic data and characteristics of their depressive episode 
 Moclobemide (n = 
22) 
Fluoxetine (n = 
19) 
All patients (n = 
41) 
Sex    
Male 13 (59%) 12 (63%) 25 (61%) 
Female 9 (41%) 7 (37%) 16 (39%) 
Age (years)    
Mean 42.3 42.4 42.3 
Minimum 27.0 28.2 27 
Maximum 55.4 54.2 55.4 
HDRS (inclusion)    
Mean 21.7 22.4 22.0 
Minimum 17 18 17 
Maximum 27 32 32 
Precipitating factor    
None 1 (5%) 2 (11%) 3 (7%) 
Somatic illness 1 (5%) 0 (0%) 1 (2%) 
Psycho-social stressors 16 (73%) 15 (79%) 31 (76%) 
Somatic illness and psycho-social 
stressors 
3 (14%) 2 (11%) 5 (12%) 
Uncertain 1 (5%) 0 (0%) 1 (2%) 
Time between last and current 
episode (months) 
   
Mean 20.3 12.6 16.8 
Minimum 1.4 0.5 0.5 
Maximum 157.7 73.8 157.5 
Characterization    
Depression with anxiety 9 (41%) 10 (53%) 19 (46%) 
Depression with mainly somatic 
symptoms 
2 (9%) 3 (16%) 5 (12%) 
Agitated depression 5 (23%) 3 (16%) 8 (20%) 
Retarded depression 3 (14%) 1 (5%) 4 (10%) 
Neurotic depression 3 (14%) 1 (5%) 4 (10%) 
Neurotic depression with anxiety 0 (0%) 1 (5%) 1 (2%) 
HDRS, Hamilton Depression Rating Scale. 
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A PRIORI COMPARISONS 
Efficacy and driving variables were evaluated in two ways: between patients’ baseline and the 
last visit for the intent-to-treat population and over all visits for those completing the study. A 
repeated measures analysis of variance was used to test for the effects of the factors drug, time 
and their interaction on HDRS, MADRS and BDI scores. Original CGI scores were compared 
between drugs for every visit separately by means of a nonparametric Mann-Whitney test. Side 
effects were evaluated using the chi-square test or in the case of too small expected frequencies, 
the Fisher exact test. 
The coefficient of correlation between all patients’ two baseline SDLP scores was calculated 
before averaging them, per patient, to a single pretreatment score. SDLP scores at baseline and 
during treatment then entered a repeated measures, multivariate analysis of variance to 
evaluate the effects of drugs, time and their interaction. Orthogonal polynomial contrasts were 
used to measure linear, quadratic and cubic trends over time. 
A POSTERIORI COMPARISONS 
A post-hoc multiple linear regression analysis was applied to determine whether other factors 
independently correlated with driving performance. Selected factors were either continuous 
variables or dichotomous indicator (0 or 1) variables. Factors belonging to the former category 
were: pretreatment SDLP (average of two baseline scores) and depression severity (MADRS). 
Those belonging to the latter were the following: antidepressant (moclobemide or fluoxetine); 
double dose (1X or 2X the starting antidepressant dose after treatment week 3); sleep 
disturbance, nervousness, nausea (presence or absence); BZD Comedication (presence or 
absence); high dose BZD Comedication [presence or absence of doses exceeding the local 
definition of ‘defined daily doses’ of Petit et al., (1994)]; competitive BZD comedication 
(presence or absence). 
The rationale for identifying certain BZDs taken by these patients as competitive with 
moclobemide and others with fluoxetine, is lengthy and is for that reason reserved for 
Discussion. For now, the former are simply listed as clorazepate, prazepam, diazepam, 
cloxazolam and clotiazepam, and the latter as bromazepam and alprazolam. 
Stepwise construction of multiple linear regression equation began with the calculation of 
product moment or biserial coefficients of correlations between each of the independent 
variables and the dependent variable, SDLP. The first independent variable considered for entry 
into a regression equation was the one with the largest positive or negative correlation with the 
dependent variable. The proportion of variance ‘explained’ by the equation (i.e. R2 or goodness 
of fit) was then evaluated relative to the residual variance by F-test. The variance entered the 
regression equation if R2 was significant. Once a variable was selected, the partial correlations 
between SDLP and each of the other independent variables not in the equation, adjusted for the 
independent variable in the equation, were used to select the next one. The independent 
variable with the largest partial correlation was the next candidate for inclusion in the equation. 
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It was entered if it was associated with a significant change in R2 as indicated by the T-test. 
Subsequently, a new set of partial correlations was calculated, again adjusted for independent 
variable(s) in the equation. Variable selection terminated when no more variables significantly 
increased R2. This analysis was separately applied on data collected after 1, 3 and 6 weeks of 
treatment. 
Results 
INTENT-TO-TREAT POPULATION AND COMPLETERS 
The intent-to-treat population comprised 41 patients of whom 22 and 19 were assigned to 
moclobemide and fluoxetine groups, respectively. Two patients withdrew after 2 and 3 weeks of 
moclobemide treatment; one for reasons unrelated to treatment and the other because of side 
effects (nervousness, agitation, sleep disturbances). Another patient’s moclobemide treatment 
was stopped after 5 weeks because the psychiatrist suspected that the patient’s might develop 
mania. This patient completed the final driving test, albeit 1 week earlier than the others. One 
patient withdrew during the first week of fluoxetine treatment because of nervousness, agitation 
and sleep disturbance. Another member of the fluoxetine group provided all clinical data but did 
not perform his last driving test because he immediately departed on a vacation. In summary, 
complete clinical data were collected for 18 and 19 patients, and complete driving data for 20 
and 17 patients in the moclobemide and fluoxetine groups, respectively. 
EFFICACY 
Descriptive statistics and results of statistical of HDRS, MADRS and BDI scores are given in Table 
II. Analysis of variance and Mann-Whitney tests provided similar results for the intent-to-treat 
population and completers. Moclobemide and fluoxetine produced similar, significant reductions 
in mean depression ratings on all scales during 6 weeks of treatment. The drugs’ similar effects 
on depressive symptoms were further demonstrated by HDRS scores at the final assessment. In 
the moclobemide group, 55% of the intent-to-treat population and 58% of the completers 
showed HDRS scores less than 10 or a decrease from baseline of more than 50%. In the 
fluoxetine group, 53 and 61% of patients showed these positive responses, respectively. CGI 
ratings at baseline and during therapy did not differ between treatment groups. 
ADVERSE EVENTS 
Nausea, nervousness/agitation, sleep disturbances and dizziness were reported by six, five, 
three and two patients in the fluoxetine group and by five, six, 11 and one patient in the 
moclobemide group. None of these frequencies differed significantly between groups. In 
addition, five patients reported dry mouth during fluoxetine treatment. 
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Table II. Hamilton Depression Rating Scale (HDRS), Montgomery-Asberg Depression Rating Scale 
(MADRS) and Beck’s Depression Inventory (BDI) scores by groups and times of assessments 
  HDRS  MADRS BDI 
Time of Assessments FLU MOC FLU MOC FLU MOC 
Baseline 22.7 20.8 28.1 26.5 16.1 15.6 
 (4.0) (3.1) (7.2) (6.2) (7.4) (5.5) 
Week 1 17.5 18.6 21.2 22.5 12.6 13.2 
 (4.8) (3.6) (8.1) (6.4) (4.7) (5.4) 
Week 2 14.6 15.9 18.5 19.6 9.7 13.7 
 (4.8) (6.7) (7.4) (9.6) (5.8) (8.7) 
Week 3 13.5 14.1 16.8 18.7 11.1 13.0 
 (5.2) (5.9) (7.7) (9.6) (7.2) (7.0) 
Week 6 11.1 12.2 13.7 14.3 9.2 10.8 
 (6.1) (5.8) (8.8) (8.5) (8.5) (6.7) 
Last visit 11.7 12.1 14.5 14.2 9.5 10.3 
 (6.6) (5.4) (9.2) 7.9 (8.3) (6.4) 
ANOVA Completers 
(n = 37) 
Intent-to-
treat            
(n = 41) 
Completers 
(n = 41) 
Intent-to-
treat            
(n = 41) 
Completers 
(n = 37) 
Intent-to-
treat            
(n = 41) 
Drugs p = 0.528 p = 0.381 p = 0.650 p = 0.667 p = 0.118 p = 0.603 
Time p < 0.001 p < 0.001 p < 0.001 p < 0.001 p < 0.001 p < 0.001 
Drugs by time p = 0.727 p = 0.654 p = 0.761 p = 0.650 p = 0.394 p = 0.877 
ANOVA, analysis of variance; FLU, fluoxetine; MOC, moclobemide 
DOSE DOUBLING AND BENZODIAZEPINE COMEDICATION 
After 3 weeks of treatment, daily dose was doubled for 14 (67%) patients in the moclobemide 
group and for six (33%) patients in the fluoxetine group (p = 0.08). BZD anxiolytics were being 
taken by 30 patients at study entrance and their use continued during treatment. One patient 
started taking BZD Comedication during the study. In total, 16 (73%) and 15 (79%) patients in 
the moclobemide and fluoxetine group, respectively, used BZD during treatment. The types of 
Comedication taken by patients in both groups, the numbers using each one and the numbers 
taking them in higher than the respective defined daily doses are given Table III. 
DRIVING PERFORMANCE: A PRIORI ANALYSES 
Fig. 1 shows the relationship between the patients’ two SDLP scores from consecutive baseline 
tests. They drove with similar SDLP (mean ± SE) values on both occasions (24.2 ± 0.95 versus 
24.1 ± 0.81 cm) and the individual values were highly reliable (r = 0.87). There was no 
difference between SDLP scores of patients who were taking BZDs and those who were not, 
either for each test separately or for both tests combined (combined mean ± SE, 24.1 ± 0.91 
versus 24.2 ± 1.59 cm: F1.39 = 0.004, p = 0.95).  
Figure 2 shows each group’s mean SDLP (SE) in baseline tests and in those given after 1, 3 and 6 
weeks of treatment. Multivariate analysis of variance revealed no significant overall mean 
differences in SDLP between the fluoxetine and moclobemide groups for either the intent-to-
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treat population or the completers. Within individuals the overall linear increase in SDLP over 
tie was significant for the intent-to-treat population and the completers (F1.38 = 5.35, p = 0.026 
and F1.35 = 5.44, p = 0.026 respectively). The interaction between drug and time was not 
significant. 
 
Table III. Number of patients receiving benzodiazepine (BZD) comedication, and doses higher than 
defined daily dose (DDD) 
 Fluoxetine (n = 19) Moclobemide (n = 22) 
BZD (DDD) No. patients Doses > DDD No. patients Doses > DDD 
Clorazepate (20 mg) - - 3 2 
Prazepam (30 mg) 1 - 21 1 
Diazepam (10 mg) 1 - 1 1 
Cloxazolam (2 mg) - - 1 1 
Clotiazepam (5 mg) - - 1 1 
Bromazepam (10 mg) 41 21 1 1 
Alprazolam (1 mg) 3 2 1 - 
Oxazepam (50 mg) 3 - 5 - 
Lorazepam (2.5 mg) 3 3 1 1 
Total cases 15 7 16 8 
1One patient only completed driving tests at baseline 
 
FIG. 1. Individual driving performance of 41 depressed 
patients at the first and second baseline tests. Thirty 
patients were benzodiazepine users (◼), others were 
nonusers (X). 
FIG. 2. Mean (± SE) standard deviation of lateral position (SDLP) 
during baseline tests and those given after 1, 3 and 6 weeks of 
therapy with fluoxetine and moclobemide. Number of patients 
participating are noted separately for groups receiving (▲, F) 
fluoxetine and (▼, M) moclobemide.  
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Table IV. Variables entering the multiple linear regression analysis and their associated p-values as 
indicated by F and T tests 
 
Slope and intercept values are shown in the column labelled B. 
BZD, benzodiazepine; SDLP, standard deviation of lateral position. 
 
DRIVING PERFORMANCE: A POSTERIORI ANALYSES 
Results from the multiple linear regression analysis are given in Table IV. The data show that 
pretreatment SDLP correlated strongly with scores measured on subsequent occasions. The 
proportions of SDLP variance ‘explained’ by pretreatment scores were 0.81, 0.78 and 0.64 after 
1, 3 and 6 weeks of therapy, respectively. That this proportion dropped between weeks 3 and 6 
implies the growing influence of other factors on the patients’ driving performance. There may 
have been several such factors but the only one to emerge as a significant determinant of SDLP 
variation was competitive BZD Comedication. Inclusion of this dichotomous variable in the 
equation increased the proportion of ‘explained’ SDLP variance by 0.02 after week 3 and by 0.05 
after week 6. 
 Week 1 Week 3 Week 6 
Variables in the 
equation 
B T  p B T  p B T  p 
(Constant) 3.88 2.45 0.018 1.67 0.83 0.394 3.52 1.31 0.198 
Pretreatment 
SDLP 
0.82 12.88 0.000 0.92 11.53 0.000 0.86 7.77 0.000 
Competitive BZD    2.04 2.46 0.019 2.81 2.39 0.023 
Multiple R  0.902   0.901   0.830  
R square 1st 
variable 
 0.813   0.779   0.635  
R square 2nd 
variable 
    0.811   0.689  
Analysis of 
variance 
F1.38 = 165.89; p < 0.001 F2.36 = 77.41; p < 0.001 F2.33 = 36.61; p < 0.001 
Variables not in 
the equation 
 p   p   p  
Antidepressants  0.707   0.612   0.236  
Double dose  not 
applicable 
  not 
applicable 
  0.842  
Depression 
severity 
 0.336   0.884   0.421  
BZD 
Comedication 
 0.210   0.201   0.340  
High doses BZD  0.801   0.419   0.790  
Competitive BZD  0.832        
Sleep 
disturbances 
 0.062   0.905   0.953  
Nervousness  0.468   0.213   0.220  
Nausea  0.463   0.491   0.196  
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Fig. 3 illustrates the effects on mean (SE) SDLP of both antidepressants, separately and together, 
in the presence or absence of competitive BZD Comedication. Although data from subgroups 
using noncompetitive and no BZD Comedication were combined in the regression analysis, their 
respective mean SDLP values are shown separately in the figure. It is clear that none of these 
subgroups’ performances changed substantially from baseline levels over the course of 
treatment. In contrast, mean SDLP rose progressively from baseline for the subgroup taking 
moclobemide in combination with competitive BZD Comedication. The subgroup taking 
fluoxetine in combination with competitive Comedication showed a similar rise in mean SDLP 
after treatment week 3 but then a recovery to baseline levels after week 6. 
 
 
FIG. 3. Mean standard deviation of lateral position (SDLP) (SE) as a function of time for subgroups of patients 
receiving (—) competitive benzodiazepine comedication, (····) noncompetitive comedication or (····) none at all 
during treatment with fluoxetine and moclobemide. 
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This was the first study to assess objectively the driving performance of depressed outpatients 
before and during antidepressant drug therapy. The purpose was to determine whether the 
drugs’ therapeutic or side effects influence patients’ driving performance. Moclobemide and 
fluoxetine produced similar remissions in the respective group’s depressive symptoms over the 
course of parallel 6-week treatment periods. It should be noted, however, that a higher 
proportion of the moclobemide group required dose-doubling to achieve this improvement (i.e. 
67 versus 33%, p = 0.08). The drugs’ side effects (nervousness, irritability and sleep 
disturbances) were likewise similar in frequency and severity. 
The patients’ baseline driving performances were reliable, as indicated by a test-retest 
correlation of 0.87. They drove with a mean SDLP of approximately24 cm during both tests. This 
is only slightly higher than mean values recorded for healthy volunteers or anxious patients in 
similar studies [i.e. 19-23 cm (Van Laar et al., (1995)]. All but one of the present patients drove 
at baseline with SDLPs that were well below the established normal limit of 35 cm. Most of them 
were chronic BZD users. Yet the users’ mean SDLP was little different from that of the minority 
who were not using BZDs. This finding confirms results from previous experimental and 
epidemiological research. Van Laar et al. (1992) treated anxious patients for 4 weeks with 
diazepam 5 mg three times a day. Their driving impairment was substantial after the first week 
but gradually diminished over time. After 4 weeks, their driving performance no longer 
significantly differed from baseline. Neutel (1995) calculated the risk of becoming involved in an 
injurious traffic accident for 148000 patients as a function of time after receiving a prescription 
for BZD anxiolytics relative to that of 98000 control individuals. Patients drove with a risk that 
was 13.5 times higher than that of the control individuals during the first week after their 
prescription were filled, but after 4 weeks the relative risk had decreased to a value of 2.6 with 
no measurable effect after that. Together these results indicate that depression itself, but not 
long-term use BZDs, was responsible for the patients’ slightly deficient driving performance at 
the time of study entry. 
The progressive remission in both groups’ depressive symptoms was not accompanied by an 
improvement in driving performance. In fact the opposite occurred; mean SDLP for all patients 
combined rose throughout the 6-week treatment period. The rising trend was very gradual but 
statistically significant. Although there was no significant difference in trends between the 
groups, that for the moclobemide group was most pronounced. This was surprising because 
moclobemide does not accumulate with repeated dosing, whereas fluoxetine and its active 
metabolite do, and to marked degrees. Thus we suspected that some factor beside or in addition 
to the antidepressants was responsible for at least some patients’ progressive deterioration in 
driving ability. Several were conceivable and the post-hoc analysis was applied in the hope of 
identifying the factor or factors responsible for the change. 
One was suggested by concern regarding antidepressant—BZD interactions involving the P450 
cytochrome system (Brøsen, 1993; Von Moltke et al., 1994). Among all of the P450 isozymes so 
far identified in humans, only CYP2C19 and two almost identical isozymes of the CYP3A 
subfamily, -3 and -4 (CYP3A3/4), respectively, are able to catalyze oxidative reactions involving 
BZDs (Ketter et al., 1995). Moclobemide is a substrate for and a relatively potent inhibitor of 
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CYP2C19 (Gram et al., 1995). Fluoxetine’s metabolite, norfluoxetine, is a potent inhibitor of 
CYP3A3/4 (Von Moltke et al., 1994). CYP3A3/4 inhibitors retard the first steps in the 
metabolism of bromazepam (3-hydroxylation: Van Harten et al., 1992) and alprazolam, 
triazolam and midazolam (n-hydroxylation: Lasher et al., 1991; Kroboth et al., 1995). Andersson 
et al., (1994) found that the inhibition both of CYP3A3/4 and of CYP2C19 retarded the N-
demethylation of diazepam to form nordiazepam, but that only the former prevented the 3-
hydroxylation of diazepam to form temazepam in vitro. Bertilsson et al. (1989) provided the 
first indication that the metabolism of nordiazepam proceeds through the polymorphic isozyme 
responsible for hydroxylation of S-mephenytoin, later identified as CYP2C19 (Wrighton et al. 
1993; Goldstein et al., 1994). They showed that clearance and elimination of diazepam and 
nordiazepam in extensive hydroxylation of S-mephenytoin proceeded at twice the rates found in 
poor metabolizers. In addition, Caraco et al. (1995) showed that concomitant administration of 
diazepam and omeprazole, a CYP2C19 inhibitor, reduced clearance of diazepam and increased 
the area under the curve of nordiazepam in extensive metabolizers. Fluoxetine also reduced 
clearance of diazepam but at the same time lowered the area under the curve of nordiazepam, 
presumably by inhibiting CYP3A3/4 (Lemberger et al., 1988). Thus the evidence so far indicates 
that whereas diazepam is N-demethylated both at CYP3A3/4 and at CYP2C19, the 3-
hydroxylation of nordiazepam occurs mainly, if not entirely, at CYP2C19. 
The effects of moclobemide on the metabolism of BZDs are still unknown but for purposes of 
analysis they were assumed to be those of a CYP2C19 inhibitor. Thus we dichotomized between 
those patients taking moclobemide with any BZD that possesses nordiazepam among its 
metabolites, and those taking another BZD or none. We further assumed that fluoxetine 
primarily inhibits CYP3A3/4. Again we dichotomized between those patients taking BZD that 
are known substrates of that isozyme, except diazepam, and those taking another BZD or none. 
The former patients in both groups were defined as taking competitive comedication, and the 
latter as taking noncompetitive comedication or none. A question arose in the case of one patient 
taking the combination of moclobemide and the little known BZD clotiazepam. The combination 
was defined as competitive, mainly because metabolism of clotiazepam proceeds by N-
demethylation and 3-hydroxylation, like that of diazepam, although more rapidly (Ochs et al., 
1984). We admit that this assignment was more arbitrary than the others. 
The dichotomization yielded interesting results in the multiple regression analysis. Its 
application with the data from the driving test after 1 week of antidepressant therapy showed 
no significant partial correlation between patients’ use of competitive BZDs and SDLP At that 
time, their performance was simply related to preexisting individual differences in SDLP, 
showing again the stability of the measure in the absence of any new factor. Subsequent 
applications with data from tests given both after week 3 and 6 indicated the emergence of a 
new factor. At these times, the dichotomous variable identifying users and nonusers of 
competitive BZDs correlated significantly with SDLP. In general, patients taking competitive 
BZDs drove progressively worse, whereas the others continued to drive in approximately the 
same manner as before. We assume that a rising brain concentration of the comedication or its 
active metabolite, because of the particular antidepressants’ inhibition of the inactivating 
isozyme, was the root cause for the former patients’ deterioration. 
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There was an apparent difference between the persistence of driving impairment in patients 
taking competitive BZD comedication with moclobemide and fluoxetine. For the moclobemide 
subgroup, mean SDLP rose throughout the 6-week treatment period, but for the fluoxetine 
subgroup, only until week 3. Maximal elevations in mean SDLP in the fluoxetine and 
moclobemide subgroups were approximately 2 and 5 cm respectively, which were close to 
elevations previously shown in social drinkers while driving with blood alcohol concentrations 
of 0.50 and 0.80 mg/ml, respectively (Louwerens et al., 1987). Possibly this difference is related 
to the respective sites of the pharmacokinetic interaction. The only known BZD substrates of 
CYP2C19, diazepam and nordiazepam, are slowly metabolized under normal circumstances. 
Except for diazepam, those of CYP3A3/4 are all more rapidly metabolized. Supposing 
moclobemide and fluoxetine/ norfluoxetine selectivity inhibit these respective isozymes to 
similar degrees, it would take longer for substrates of CYP2C19 to reach a new steady state than 
for substrates of CYP3A3/4. This does not imply that the interaction of moclobemide with 
competitive BZDs is any more consequential for patient safety than that of fluoxetine. It might 
have appeared that way if all of the patients had been taking nordiazepam during the study. 
However, exactly the opposite impression might have been given if they had been taking 
alprazolam. 
The dual purpose of every post-hoc analysis is to explain simultaneously an unforseen result and 
provide hypotheses for further research. Some explanations for the unforseen deterioration in 
some patients’ driving performance at a relatively late stage during their treatment with study 
medication seemed necessary in view of the likelihood that the same could occur in real life. Our 
explanation is for the moment tentative and mainly of heuristic value. Well-controlled studies 
should now be undertaken to determine which antidepressant—BZD combinations are and are 
not compatible with patient safety as they engage in potentially dangerous activities, like 
driving. 
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